TWI612966B - A use of an extract of asplenium australasicum (j. sm.) hook. - Google Patents
A use of an extract of asplenium australasicum (j. sm.) hook. Download PDFInfo
- Publication number
- TWI612966B TWI612966B TW106118699A TW106118699A TWI612966B TW I612966 B TWI612966 B TW I612966B TW 106118699 A TW106118699 A TW 106118699A TW 106118699 A TW106118699 A TW 106118699A TW I612966 B TWI612966 B TW I612966B
- Authority
- TW
- Taiwan
- Prior art keywords
- extract
- nanyangshan
- nanyangshan sushui
- sushui extract
- nanyangshansu
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 37
- 241001312267 Asplenium australasicum Species 0.000 title description 2
- 206010061218 Inflammation Diseases 0.000 claims abstract description 18
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 8
- -1 IL-1β Proteins 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241001453169 Asplenium Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010034344 Peptic ulcer haemorrhage Diseases 0.000 description 1
- 206010034354 Peptic ulcer perforation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一種南洋山蘇水萃物的用途，係用以製備抑制革蘭氏陰性菌感染所造成之發炎的藥物，其中，該南洋山蘇水萃物係以水作為一萃取溶劑，於115~125℃之溫度、0.35~0.5Kg/cm2G之壓力下萃取一南洋山蘇樣品1.5~3小時所獲得。 The use of a Nanyangshan Sushui extract for the preparation of a medicament for inhibiting inflammation caused by Gram-negative bacteria infection, wherein the Nanyangshan Sushui extract uses water as an extraction solvent at 115-125 ° C The temperature was extracted at a pressure of 0.35 to 0.5 kg/cm 2 G for 1.5 to 3 hours.
Description
本發明係關於一種南洋山蘇水萃物的用途，特別關於一種南洋山蘇水萃物應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物的用途。 The invention relates to the use of a Nanyangshan Sushui extract, in particular to a use of a Nanyangshan Sushui extract for the preparation of a medicament for inhibiting inflammation caused by Gram-negative infection.
脂多糖(lipopolysaccharide)又稱作內毒素(endotoxin)，是革蘭氏陰性菌(Gram-negative bacteria)外膜的主要組成部分，提供細菌以結構的完整性(structural integrity)，並保護細菌膜受某些化學物質的攻擊。當動物體遭受革蘭氏陰性菌感染時，其巨噬細胞(macrophage)會釋放出TNF-α、IL-1β、IL-6等促發炎細胞激素(proinflammatory cytokine)，這些細胞激素會提升血管通透性(vascular permeability)，導致熱(fever)、痛(pain)、腫(swelling)等發炎反應，並刺激活化巨噬細胞分泌更多促進發炎的細胞激素而造成發炎反應。 Lipopolysaccharide, also known as endotoxin, is a major component of the outer membrane of Gram-negative bacteria, providing the structural integrity of bacteria and protecting bacterial membranes. Attack by certain chemicals. When the animal is infected with Gram-negative bacteria, its macrophage releases proinflammatory cytokine such as TNF-α, IL-1β, IL-6, which promotes vascular access. Vascular permeability, which causes inflammatory reactions such as fever, pain, and swelling, and stimulates activated macrophages to secrete more inflammatory cytokines that cause inflammation.
一般而言，發炎是身體為移除有害病原體及促進組織修復的保護措施，但是長期發炎將造成人體不適，甚或惡化而破壞生理組織導致壞死；因此發炎反應一旦發生，應密切注意並避免惡化。 In general, inflammation is a protective measure for the body to remove harmful pathogens and promote tissue repair, but long-term inflammation will cause discomfort, or even worsen, and damage the physiological tissue leading to necrosis; therefore, once the inflammatory reaction occurs, close attention should be paid to avoid deterioration.
吲哚美辛(indomethacin)為一種習用抑制革蘭氏陰性菌感染所造成之發炎的的藥物，主要用以抑制發炎反應所造成的熱、痛、腫等現象，惟其卻可能導致消化性潰瘍(peptic ulcers)而造成嚴重的出血(bleeding)或穿孔(perforated peptic ulcer)，是以，確實仍有必要發展新 的抑制革蘭氏陰性菌感染所造成之發炎的藥物。 Indomethacin (indomethacin) is a drug used to inhibit the inflammation caused by Gram-negative infections. It is mainly used to suppress the heat, pain, swelling and other phenomena caused by the inflammatory reaction, but it may cause peptic ulcer ( Peptic ulcers) cause severe bleeding or perforated peptic ulcer, so it is still necessary to develop new An anti-inflammatory drug caused by the infection of Gram-negative bacteria.
為解決上述問題，本發明提供一種南洋山蘇水萃物的用途，係將萃取自南洋山蘇之活性成分，應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物者。 In order to solve the above problems, the present invention provides a use of an extract of Nanyangshan Sushui, which is an active ingredient extracted from Nanyangshansu, which is used for preparing a medicament for inhibiting inflammation caused by Gram-negative infection.
本發明之南洋山蘇水萃物的用途，係應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物，其中，該南洋山蘇水萃物係水於115~125℃之溫度、0.35~0.5Kg/cm2G之壓力下萃取1.5~3小時所獲得；如此藉由萃取自南洋山蘇之活性成分，可以抑制脂多糖所誘導之TNF-α、IL-1β、IL-6等促發炎細胞激素的生成，藉此降低發炎反應的發生，因而可以應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物，為本發明之功效。 The use of the Nanyangshan Sushui extract of the present invention is applied to the preparation of a medicament for inhibiting inflammation caused by Gram-negative bacteria infection, wherein the water of the Nanyangshan Sushui extract is at a temperature of 115 to 125 ° C, 0.35 It can be obtained by extracting under the pressure of ~0.5Kg/cm 2 G for 1.5~3 hours; thus, by extracting the active ingredients from Nanyangshansu, it can inhibit the TNF-α, IL-1β, IL-6 induced by lipopolysaccharide. The production of inflammatory cytokines, thereby reducing the occurrence of inflammatory reactions, can be applied to the preparation of a medicament for inhibiting inflammation caused by Gram-negative infection, and is an effect of the present invention.
第1圖：投予本發明南洋山蘇水萃物對RAW264.7細胞株之存活率的影響結果柱狀圖。 Fig. 1 is a bar graph showing the effect of administration of the Nanyangshan Sushui extract of the present invention on the survival rate of RAW264.7 cell line.
第2a圖：投予本發明南洋山蘇水萃物對RAW264.7細胞株之TNF-α RNA生成量的影響結果柱狀圖。 Fig. 2a is a histogram showing the effect of the Nanyangshan Sushui extract of the present invention on the amount of TNF-α RNA produced by the RAW264.7 cell line.
第2b圖：投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-1β RNA生成量的影響結果柱狀圖。 Fig. 2b is a bar graph showing the effect of the Nanyangshan Sushui extract of the present invention on the amount of IL-1β RNA produced by the RAW264.7 cell line.
第2c圖：投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-6 RNA生成量的影響結果柱狀圖。 Fig. 2c is a bar graph showing the effect of the Nanyangshan Sushui extract of the present invention on the amount of IL-6 RNA produced by the RAW264.7 cell line.
第3a圖：投予本發明南洋山蘇水萃物對RAW264.7細胞株之TNF-α蛋白質分泌量的影響結果柱狀圖。 Fig. 3a is a histogram showing the effect of the Nanyangshan Sushui extract of the present invention on the amount of TNF-α protein secreted by the RAW264.7 cell line.
第3b圖：投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-1β 蛋白質分泌量的影響結果柱狀圖。 Figure 3b: Administration of the IL-1β of the RAW264.7 cell line of the Nanyangshan Sushui extract of the present invention The histogram of the effect of protein secretion on the histogram.
第3c圖：投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-6蛋白質分泌量的影響結果柱狀圖。 Fig. 3c is a bar graph showing the effect of the Nanyangshan Sushui extract of the present invention on the secretion of IL-6 protein in RAW264.7 cell line.
為讓本發明之上述及其他目的、特徵及優點能更明顯易懂，下文特舉本發明之較佳實施例，並配合所附圖式，作詳細說明如下：本發明所述之「南洋山蘇(Asplenium australasicum(J.Sm.)Hook.)」，係指鐵角蕨科(Aspleniaceae)鐵角蕨屬(Asplenium)的植物，其新生嫩葉(young emerging frond)常被作為食用菜葉。 The above and other objects, features and advantages of the present invention will become more <RTIgt; Asplenium australasicum (J.Sm.) Hook.) refers to the plant of the Asplenaceae Asplenium , whose young emerging frond is often used as a edible leaf.
本發明之南洋山蘇水萃物，係可以抑制脂多糖所誘導之TNF-α、IL-1β、IL-6等促發炎細胞激素的生成，藉此降低發炎反應的發生，因而可以應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物，該南洋山蘇水萃物與醫藥學上可以接受之載劑或賦形劑組合形成一醫藥組合物，其中，該南洋山蘇水萃物係可以製備成任何方便食用之型式，如錠劑、膠囊、粉劑、粒劑或液劑等，或者將該南洋山蘇水萃物與其他食品或飲料組合，以適於食用之樣態供生物體以口服方式服用。 The Nanyangshan Sushui extract of the invention can inhibit the production of inflammatory cytokines such as TNF-α, IL-1β, IL-6 induced by lipopolysaccharide, thereby reducing the occurrence of inflammatory reaction, and thus can be applied to preparation The medicine for inhibiting inflammation caused by Gram-negative bacteria infection, the Nanyangshan Sushui extract is combined with a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, wherein the Nanyangshan Sushui extract It can be prepared into any convenient form, such as tablets, capsules, powders, granules or liquids, or the Nanyangshan Sushui extract can be combined with other foods or beverages to be suitable for eating. The body is taken orally.
其中，該南洋山蘇水萃物較佳係可以藉由一包含以下步驟之方法所製得：提供一南洋山蘇樣品；以水作為一萃取溶劑萃取該南洋山蘇樣品；及將南洋山蘇粗萃液進行濃縮，以獲得該南洋山蘇水萃物。 Wherein, the Nanyangshan Sushui extract can be obtained by a method comprising the steps of: providing a sample of Nanyangshansu; extracting the sample of Nanyangshansu with water as an extraction solvent; and using Nanyangshansu The crude extract is concentrated to obtain the aqueous extract of Nanyangshansu.
詳而言之，該南洋山蘇樣品係可以為南洋山蘇之成熟老葉(三年以上，背面分布孢子)，較佳係可以預先將該南洋山蘇樣品於110~120℃之溫度下進行乾燥(將100克南洋山蘇樣品乾燥至20克)，得到一南洋山蘇乾燥物；此外，該南洋山蘇樣品亦可以預先碎成粉粒(粒徑約為1~2mm)，以增加該南洋山蘇樣品與該萃取溶劑之接觸表面積，藉此提升後續萃取之萃取效率。 In detail, the sample sample of Nanyangshansu may be mature mature leaves of Nanyangshansu (more than three years, spores are distributed on the back), and it is preferable to carry out the sample of Nanyangshansu in advance at a temperature of 110-120 °C. Drying (100 g of Nanyangshansu sample is dried to 20 g) to obtain a dried Nanyangshan Su; in addition, the Nanyangshansu sample can also be pre-crushed into powder (having a particle size of about 1 to 2 mm) to increase the The contact surface area of the Nanyangshansu sample with the extraction solvent, thereby improving the extraction efficiency of the subsequent extraction.
舉例而言，每4.8kg之南洋山蘇樣品係能夠混合該萃取溶劑，使二者總體積達80L，並於115~125℃之溫度、0.35~0.5Kg/cm2G之壓力下進行萃取1.5~3小時，上述萃取亦可以重複數次，使該南洋山蘇樣品所富含之活性成分可以完整溶出於該萃取溶劑，此為本發明所屬技術領域中具有通常知識者所廣泛應用，在此不加以贅述。 For example, each 4.8 kg of Nanyangshansu sample can mix the extraction solvent to a total volume of 80 L, and extract at a temperature of 115-125 ° C and a pressure of 0.35-0.5 Kg/cm 2 G. ~3 hours, the above extraction may also be repeated several times, so that the active ingredient rich in the sample of Nanyangshansu can be completely dissolved in the extraction solvent, which is widely used by those having ordinary knowledge in the technical field of the invention. Do not repeat them.
前述之南洋山蘇粗萃液可以經過減壓濃縮及冷凍乾燥，以獲得該南洋山蘇水萃物，藉由此一程序，係可以使該南洋山蘇水萃物之活性成分更加濃縮，是以僅需使用少量之該南洋山蘇水萃物即可以發揮最佳療效。 The aforementioned Nanyangshan Su crude extract liquid can be concentrated under reduced pressure and freeze-dried to obtain the Nanyangshan Sushui extract. By this procedure, the active ingredient of the Nanyangshan Sushui extract can be more concentrated. The best effect can be achieved by using only a small amount of the Nanyangshan Sushui extract.
為證實本發明之南洋山蘇水萃物係可以抑制TNF-α、IL-1β、IL-6等細胞激素的生成，遂進行以下試驗。 In order to confirm that the Nanyangshan Sushui extract of the present invention can inhibit the production of cytokines such as TNF-α, IL-1β, and IL-6, the following test was carried out.
(A)南洋山蘇水萃物對細胞存活率的影響 (A) Effect of Nanyangshan Sushui Extract on Cell Survival Rate
請參照第1表所示，本試驗係分別以不同濃度之南洋山蘇水萃物處理RAW264.7細胞株1小時後，加入LPS(1μg/mL)處理24小時，續以CellTiter 96 AQueous One Solution Cell Proliferation Assay之方式偵測各組細胞的存活率，其結果如第1圖所示。 Please refer to the first table. The RAW264.7 cell line was treated with different concentrations of Nanyangshan Sushui extract for 1 hour, then added with LPS (1μg/mL) for 24 hours, followed by CellTiter 96 AQueous One Solution. The Cell Proliferation Assay method detects the survival rate of each group of cells, and the results are shown in Fig. 1.
請參照第1圖所示，濃度為50μL/mL以下的南洋山蘇水萃物對RAW264.7細胞株不具細胞毒性(第A1~A4組)。 Referring to Fig. 1, the Nanyangshan Sushui extract with a concentration of 50 μL/mL or less is not cytotoxic to RAW264.7 cells (Groups A1 to A4).
(B)南洋山蘇水萃物對促發炎細胞激素生成量的影響 (B) Effect of extract of Nanyangshan Sushui on the production of inflammatory cytokines
請參照第2表所示，本試驗係分別以不同濃度之南洋山蘇水萃物處理RAW264.7細胞株1小時後，加入LPS(1μg/mL)處理24小時，續收取各組細胞的總RNA，進行反轉錄反應後，利用對應的引子對偵測其中的TNF-α、IL-1β、IL-6等促發炎細胞激素的RNA含量，其結果分別如第2a、2b、2c圖所示。 Please refer to the second table. The RAW264.7 cell line was treated with different concentrations of Nanyangshan Sushui extract for 1 hour, then added with LPS (1μg/mL) for 24 hours, and the total number of cells in each group was continuously collected. After RNA is subjected to reverse transcription reaction, the corresponding primers are used to detect the RNA content of inflammatory cytokines such as TNF-α, IL-1β, IL-6, etc., and the results are shown in Fig. 2a, 2b, and 2c, respectively. .
請參照第2a~2c圖所示，南洋山蘇水萃物的處理均能夠抑制TNF-α、IL-1β、IL-6等促發炎細胞激素的RNA表現，且抑制效果具有劑量依賴性。 Please refer to the figures 2a~2c. The treatment of Nanyangshan Sushui extract can inhibit the expression of TNF-α, IL-1β, IL-6 and other inflammatory cytokines, and the inhibitory effect is dose-dependent.
(C)南洋山蘇水萃物對促發炎細胞激素分泌量的影響 (C) Effect of extract of Nanyangshan Sushui on the secretion of inflammatory cytokines
請參照第3表所示，本試驗係分別以不同濃度之南洋山蘇水萃物處理RAW264.7細胞株1小時後，加入LPS(1μg/mL)處理24小時， 續收取各組的細胞上清液，以ELISA之方式偵測其中的TNF-α、IL-1β、IL-6等促發炎細胞激素的蛋白質含量，其結果分別如第3a、3b、3c圖所示。 Please refer to Table 3 for the treatment of RAW264.7 cell line with different concentrations of Nanyangshan Sushui extract for 1 hour, then add LPS (1μg/mL) for 24 hours. The cell supernatant of each group was continuously collected, and the protein content of inflammatory cytokines such as TNF-α, IL-1β and IL-6 was detected by ELISA, and the results were as shown in Figures 3a, 3b and 3c, respectively. Show.
請參照第3a~3c圖所示，南洋山蘇水萃物的處理均能夠抑制TNF-α、IL-1β、IL-6等促發炎細胞激素的蛋白質分泌量，且抑制效果具有劑量依賴性。 Please refer to the figures 3a~3c. The treatment of Nanyangshan Sushui extract can inhibit the secretion of inflammatory cytokines such as TNF-α, IL-1β and IL-6, and the inhibitory effect is dose-dependent.
綜合上述，本發明之南洋山蘇水萃物的用途係藉由萃取自南洋山蘇之活性成分，可以抑制脂多糖所誘導之TNF-α、IL-1β、IL-6等促發炎細胞激素的生成，藉此降低發炎反應的發生，因而可以應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物，為本發明之功效。 In summary, the use of the Nanyangshan Sushui extract of the present invention can inhibit the inflammatory cytokines induced by lipopolysaccharide, such as TNF-α, IL-1β, IL-6, etc. by extracting the active ingredient from Nanyangshansu. It is produced, thereby reducing the occurrence of an inflammatory reaction, and thus can be applied to the preparation of a drug which inhibits inflammation caused by Gram-negative bacteria infection, and is an effect of the present invention.
雖然本發明已利用上述較佳實施例揭示，然其並非用以限定本發明，任何熟習此技藝者在不脫離本發明之精神和範圍之內，相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇，因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 While the invention has been described in connection with the preferred embodiments described above, it is not intended to limit the scope of the invention. The technical scope of the invention is protected, and therefore the scope of the invention is defined by the scope of the appended claims.
Claims (1)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW106118699A TWI612966B (en) | 2017-06-06 | 2017-06-06 | A use of an extract of asplenium australasicum (j. sm.) hook. |
| PCT/US2018/034863 WO2018226447A1 (en) | 2017-06-06 | 2018-05-29 | Method for inhibiting inflammation caused by gram-negative bacteria infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW106118699A TWI612966B (en) | 2017-06-06 | 2017-06-06 | A use of an extract of asplenium australasicum (j. sm.) hook. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TWI612966B true TWI612966B (en) | 2018-02-01 |
| TW201902503A TW201902503A (en) | 2019-01-16 |
Family
ID=62014374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106118699A TWI612966B (en) | 2017-06-06 | 2017-06-06 | A use of an extract of asplenium australasicum (j. sm.) hook. |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TWI612966B (en) |
| WO (1) | WO2018226447A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226447A1 (en) * | 2017-06-06 | 2018-12-13 | Jin Xin Biotechnology Co., Ltd. | Method for inhibiting inflammation caused by gram-negative bacteria infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1819356A4 (en) * | 2004-11-18 | 2010-07-07 | Biopharmacopae Design Internat | Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof |
| CN120478728A (en) * | 2016-02-12 | 2025-08-15 | 渥太华大学 | Decellularized cell wall structures of plants and fungi and their use as scaffold materials |
| TWI605821B (en) * | 2017-01-16 | 2017-11-21 | 景鑫生物科技股份有限公司 | A use of an extract of asplenium australasicum (j. sm.) hook. |
| TWI612966B (en) * | 2017-06-06 | 2018-02-01 | 景鑫生物科技股份有限公司 | A use of an extract of asplenium australasicum (j. sm.) hook. |
-
2017
- 2017-06-06 TW TW106118699A patent/TWI612966B/en not_active IP Right Cessation
-
2018
- 2018-05-29 WO PCT/US2018/034863 patent/WO2018226447A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| Lih-Shiuh Lai et al,"Chemical compositions and some physical properties of the water and alkali-extracted mucilage from the young fronds of Asplenium australasicum (J. Sm.) Hook", Food Hydrocolloids, 2012, 26(2): 344-349. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226447A1 (en) * | 2017-06-06 | 2018-12-13 | Jin Xin Biotechnology Co., Ltd. | Method for inhibiting inflammation caused by gram-negative bacteria infection |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018226447A1 (en) | 2018-12-13 |
| TW201902503A (en) | 2019-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI612966B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. | |
| CN104873579B (en) | The application of Jia Betel extracts | |
| CN103751316B (en) | A kind of there is antifungal activity waistcoat seed extract and all kinds of preparation and application | |
| CN110072517A (en) | The method for treating the viral hepatitis type b that how there is drug resistance to liver | |
| TWI595881B (en) | Use of Nanyangshan Sushui Extract | |
| JP6980791B2 (en) | Composition for the prevention or treatment of gastritis or gastric ulcer | |
| CN113166213B (en) | Bee venom purification method including virus removal process and composition for preventing or treating inflammatory disease using the same | |
| CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
| JP6076361B2 (en) | Application of Albizziachinensis extract in the preparation of medicament for the treatment of gastric ulcer | |
| CN102614242A (en) | Dropping pill of isatis root and folium isatidis and preparing method thereof | |
| CN103239538B (en) | A kind of gastropathy drug composition of anti-helicobacter pylori | |
| TWI612968B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. | |
| KR101687770B1 (en) | COMPOSITION COMPRISING EXTRACT OF Eriocaulon decemflorum HAVING ANTI-INFLAMMATORY AND ANTI-OXIDANT ACTIVITY | |
| CN104605160B (en) | A kind of compositions preventing and treating sow puerperal endometritis and application thereof | |
| TWI615146B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. | |
| TWI624264B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. | |
| TWI611806B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. | |
| Ramesh et al. | Phytochemical and in vitro antimicrobial assay of fruit extracts of Morinda tinctoria Roxb | |
| Kim et al. | Anti-gastritis and anti-oxidant effects of Chenopodium album Linne fractions and betaine | |
| KR101651948B1 (en) | Anti-Coronavirus Composition | |
| CN105030954B (en) | A kind of composition, preparation, preparation method and applications for treating grice diarrhoea | |
| CN105232573A (en) | Application of radix bupleuri polysaccharide in preparing medicine for preventing and treating vaccinum influenzae vivum and virus pneumonia | |
| CN103610712A (en) | Application of sunset abelmoschus flowers and extract thereof to preparation of inflammatory bowel disease prevention and treatment medicament | |
| CN102008693B (en) | Throat-moistening and inflammation-eliminating buccal tablets containing natural essential oil of zingiber corallinum hance | |
| TW202116334A (en) | Complex for preventing or improving gastric diseases and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |